固生堂(02273.HK)公開發售獲超額認購2.84倍 上限定價每股29港元
格隆匯12月9日丨固生堂(02273.HK)發佈公吿,公司全球發售2787.8萬股股份,其中香港發售股份278.78萬股,國際發售股份2509.02萬股,另有15%超額配股權;最終發售價已釐定為每股發售股份29.00港元,每手買賣單位100股;BofA SECURITIES、及海通國際為聯席保薦人;預期股份將於2021年12月10日於聯交所主板掛牌上市。
香港發售股份已獲適度超額認購,合共接獲11,087份有效申請,認購合共791.74萬股,相當於香港公開發售項下初步可供認購香港發售股份總數約2.84倍。國際發售項下初步提呈發售的發售股份已獲適度超額認購,相當於國際發售項下初步可供認購發售股份總數的約4.4倍。按最終發售價每股29.00港元及根據基石投資協議,基石投資者已按最終發售價認購合共1124.13萬股,認購總金額為4200萬美元(約3.26億港元)。
假設超額配股權未獲行使,按最終發售價每股29.00港元計,公司將收取的全球發售所得款項淨額估計約為7.051億港元。公司現時擬將所得款項淨額約69.8%用於拓展公司的線上線下業務,加強線上線下業務融合;約9.6%將用於加強公司的研發能力,包括院內製劑以及中醫解決方案包的研發;約9.6%將用於加強公司的供應鏈能力,包括根據業務擴張計劃升級現有煎藥中心及建立新煎藥中心,並根據業務需要在中長期內建立自有GMP廠;約4.9%用於營銷及品牌活動;及約6.0%用於營運資金和一般企業用途。倘超額配股權獲悉數行使,公司將就於超額配股權獲行使後將予發行的418.17萬股額外股份收取約1.14億港元的額外所得款項淨額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.